Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.371
-0.002 (-0.62%)
Nov 20, 2024, 4:00 PM EST - Market closed

Cyclacel Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Revenue
0.070.42----
Upgrade
Revenue Growth (YoY)
-80.98%-----
Upgrade
Cost of Revenue
-----4.66
Upgrade
Gross Profit
0.070.42----4.66
Upgrade
Selling, General & Admin
6.326.727.387.465.885.02
Upgrade
Research & Development
9.2919.1620.2714.934.76-
Upgrade
Operating Expenses
15.6125.8727.6622.3910.645.02
Upgrade
Operating Income
-15.54-25.45-27.66-22.39-10.64-9.68
Upgrade
Interest & Investment Income
0.030.270.210.020.040.22
Upgrade
Currency Exchange Gain (Loss)
-0.35-0.410.230.040.020.1
Upgrade
Other Non Operating Income (Expenses)
0.050.051.30.140.890.23
Upgrade
EBT Excluding Unusual Items
-15.83-25.55-25.92-22.19-9.68-9.13
Upgrade
Pretax Income
-15.83-25.55-25.92-22.19-9.68-9.13
Upgrade
Income Tax Expense
-2.4-3-4.72-3.73-1.24-1.3
Upgrade
Earnings From Continuing Operations
-13.43-22.56-21.2-18.46-8.45-7.83
Upgrade
Net Income
-13.43-22.56-21.2-18.46-8.45-7.83
Upgrade
Preferred Dividends & Other Adjustments
0.050.20.20.23.980.2
Upgrade
Net Income to Common
-13.48-22.76-21.4-18.66-12.42-8.03
Upgrade
Shares Outstanding (Basic)
211100
Upgrade
Shares Outstanding (Diluted)
211100
Upgrade
Shares Change (YoY)
115.38%13.38%26.10%145.67%345.23%34.95%
Upgrade
EPS (Basic)
-7.47-26.75-28.52-31.35-51.28-147.62
Upgrade
EPS (Diluted)
-7.47-26.75-28.52-31.35-51.30-147.62
Upgrade
Free Cash Flow
--16.12-20.83-18.57-8.03-9.46
Upgrade
Free Cash Flow Per Share
--18.94-27.76-31.20-33.15-173.83
Upgrade
Gross Margin
100.00%100.00%----
Upgrade
Operating Margin
-20994.59%-6060.24%----
Upgrade
Profit Margin
-18217.57%-5418.10%----
Upgrade
Free Cash Flow Margin
--3837.62%----
Upgrade
EBITDA
-15.52-25.42-27.62-22.35-10.62-9.66
Upgrade
D&A For EBITDA
0.010.030.030.040.020.02
Upgrade
EBIT
-15.54-25.45-27.66-22.39-10.64-9.68
Upgrade
Revenue as Reported
0.40.42----
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.